This work highlights the importance of cancer cell intrinsic actions of estrogen receptor modulators in their therapeutic efficacy.
This study demonstrates that 27-hydroxycholesterol is a/the biochemical link between hypercholesterolemia/dyslipidemia and increased breast cancer risk and poor response to endocrine therapies. It resulted in several significant clinical trials to evaluate the impact of modulating 27-hydroxycholesterol on endocrine therapy in breast cancer.
Determined the mechanisms by which ERRα impacts breast cancer pathobiology and validated this receptor as a therapeutic target in cance
Identified and characterized a coregulator mutation which results in familial prostate cancer.
A discovery platform that exploits differential coregulator/NR interaction profiles to drive new drug discovery.
Defined the molecular mechanisms underlying the non-genomic actions of estrogens.
Demonstrated that receptor conformation and differential presentation of protein-protein interaction surfaces are the primary determinants of ER pharmacology and demonstrated the utility of disrupting protein-protein interaction surfaces as a therapeutic approach.
Study challenged the classical models of ER antagonist action and first to propose “functional allostery”.
Genetic evidence that cellular factors distal to the receptor influence nuclear receptor pharmacology.
Sites@Duke Express is powered by WordPress. Read the Sites@Duke Express policies and FAQs, or request help.